News from vivus, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 08, 2011, 08:00 ET

SEQUEL Trial Results for Qnexa® Published in AJCN Show 10% Sustained Weight Loss Over 2 Years

 VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the SEQUEL study were published in The American Journal of Clinical...

Dec 07, 2011, 06:45 ET

Weight Loss and Effects on Diabetes with Qnexa Treatment Results Presented at the World Diabetes Congress

 VIVUS, Inc. (NASDAQ: VVUS) announced that an oral presentation was given at the International Diabetes Federation's World Diabetes...

Dec 05, 2011, 06:45 ET

Avanafil Data Presented at the European Society of Sexual Medicine Meeting

 VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented over the weekend at the 2011 European Society of...

Dec 01, 2011, 06:45 ET

VIVUS to Present at the Deutsche Bank BioFEST Conference

 VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 2011...

Nov 14, 2011, 06:45 ET

15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting

VIVUS, Inc. (NASDAQ: VVUS) today announced that new analyses from TA-314, a phase 3 long-term safety and efficacy study of the investigational drug...

Nov 10, 2011, 06:45 ET

Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting

Highlights from Avanafil Development Program Include: - Early onset of action observed in placebo-controlled trials - Comparative...

Nov 07, 2011, 16:00 ET

VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results

VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today...

Nov 03, 2011, 17:00 ET

Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment

VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the 56-week EQUIP study were published in Obesity, the peer-reviewed journal of The...

Nov 03, 2011, 12:15 ET

FDA Accepts New Drug Application Filing for Qnexa

VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug...

Nov 03, 2011, 06:45 ET

VIVUS to Present at the Credit Suisse 2011 Healthcare Conference

VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the...

Oct 17, 2011, 06:45 ET

VIVUS Resubmits Qnexa NDA to the FDA

VIVUS, Inc. (NASDAQ: VVUS) today announced that the company has resubmitted the New Drug Application (NDA) for Qnexa® to the U.S. Food and...

Oct 14, 2011, 06:45 ET

VIVUS to Present at the BioCentury NewsMakers Conference

VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 2011...

Oct 03, 2011, 08:45 ET

Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss

                        ...

Sep 29, 2011, 06:45 ET

Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society

VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at Obesity 2011, the 29th Annual Scientific Meeting of The...

Sep 26, 2011, 06:45 ET

Topiramate Exposure and Fetal Outcomes in Migraine Patients to Be Presented at the 136th ANA Annual Meeting

VIVUS, Inc. (NASDAQ: VVUS) today announced that a poster authored by Dr. Mark W. Green, Director of the Center for Headache and Pain Medicine and...

Sep 22, 2011, 06:45 ET

10% Weight Loss Could Save Medicare $35 Billion

VIVUS, Inc. (NASDAQ: VVUS) reported that in the opening keynote address at the 6th Annual Obesity and Wellness Congress in Washington DC today,...

Sep 16, 2011, 06:45 ET

Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting

VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented at the 47th European Association for the Study of Diabetes (EASD)...

Sep 15, 2011, 06:45 ET

VIVUS Provides Regulatory Update on QNEXA

VIVUS, Inc. (NASDAQ: VVUS) today announced that following a recent teleconference it has reached agreement with officials of the Endocrine and...

Sep 13, 2011, 06:45 ET

Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting

VIVUS, Inc. (NASDAQ: VVUS) today presented positive results from the avanafil phase 3 study in diabetics.  In the REVIVE-Diabetes study...

Sep 01, 2011, 16:00 ET

VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction

VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's new drug...